Table of Contents
RNA Therapeutics Market Structure
This RNA therapeutics and delivery platform analysis indicates that in the context of domestic listed companies, the importance of platforms, delivery, and production infrastructure outweighs that of existing ADCs or radiopharmaceuticals. This structure presents new possibilities for drug development.
The domestic stock market does not feature many purely RNA therapeutic companies like in the U.S. Instead, it is closer to a mixed form of new drug development, delivery technology, CDMO, raw materials, and production platforms.
To summarize, key companies include Olix, Algenomics, and ST Pharm, with a separate classification of early delivery platform candidates and related infrastructure companies being practical. These diverse elements well illustrate the characteristics of Korea's RNA therapeutics market.
The overall structure can be summarized as follows.
The company directly responsible for RNA drug development is Olix. Algenomics is a provider of next-generation RNA editing technology. ST Pharm possesses LNP, CDMO, and production infrastructure, while early delivery platform candidates include Naybec, Aptamer Science, and OliPass. Peripheral infrastructure-related companies include Quratis and Cellumed.
Recommended Readings for Bio Stock Investment
Olix Stock Evaluation
Among domestic listed companies, Olix stands out in the field of RNA drug development. The company focuses on drug development based on RNA interference technology and has secured significant licensing agreements with global pharmaceutical companies, making a prominent mark in the domestic RNA therapeutics market.
Olix's accomplishments are significant, especially as global pharmaceutical companies seriously evaluate the expansion potential of its assets and platforms. This achievement is a key factor driving the advancement of RNA therapeutics.
Olix's advantage lies in its multifaceted structure through various platforms, not just a single candidate compound. The company possesses several technologies, including asiRNA, cp-asiRNA, and GalNAc-asiRNA; particularly, GalNAc-asiRNA is an established method targeting liver cells that has been validated in the global market.
Therefore, at this point, if focusing on a single stock, Olix may be the first company to consider. However, it is currently not in a stage of significant commercial sales, and the progress of development with Lilly and the reproducibility of subsequent technology export are crucial variables right now.
Algenomics Next-Generation Potential
Algenomics is regarded as a company with outstanding technological innovation in the RNA therapeutics field.
However, it is not appropriate to categorize this company simply as a typical siRNA or LNP company. The core technology of the company focuses on an RNA editing and correction platform based on RNA substitution enzymes, and its delivery method is closer to utilizing adenoviruses rather than traditional LNP methods.
In conclusion, it is more appropriate to classify Algenomics as a developer of gene therapies based on RNA editing technology rather than as a RNA delivery platform stock.
Algenomics possesses several key investment points. First, it holds unique advantages in RNA editing and correction technologies. Secondly, it is conducting clinical research on hepatocellular carcinoma and glioblastoma. Thirdly, it receives institutional support such as ODD and Fast Track, providing positive momentum. Fourthly, it is recognized as a rare high-freshness RNA technology company in Korea.
However, the innovation of the technology and the speed of commercialization are separate issues. Algenomics is a highly interesting company, but it must be kept in mind that it is currently in the early clinical stage.
Thus, if Olix is viewed as a realistic investment target, Algenomics is appropriately regarded as a representative of next-generation RNA editing.
ST Pharm's Infrastructure Strengths
ST Pharm is not a company that directly sells RNA therapeutics like Olix or Algenomics. Rather, it is more of an infrastructure provider playing an essential role in the value chain of RNA therapeutics.
The main business models involve CDMO for oligonucleotide therapeutics and delivery and production infrastructures related to mRNA such as SmartCap, STLNP, and SmartLNP. Given the high potential for this infrastructure to expand alongside the growth of the RNA therapeutics market, ST Pharm is positioned as a core player in the market.
ST Pharm has several key strengths. First, it stands out in the CDMO sector for oligonucleotide therapeutics. Second, it utilizes SmartCap, a 5’ capping technology, and third, it is gaining attention with STLNP, an LNP delivery technology. These elements encompass a structure that integrates raw materials, production, and delivery infrastructure.
As a result, if looking for delivery platforms like LNP among domestic listed companies, ST Pharm first comes to mind. This suggests that the domestic stock market is still more advanced in delivery and production infrastructure than in pure RNA drug stocks. In this context, ST Pharm's role appears even more critical.
Early Candidates and Peripheral Stocks
Currently, the companies mentioned as early delivery platform candidates have a strong peripheral infrastructure character.
For example, Naybec presents possibilities for delivering mRNA, siRNA, and miRNA into cells. Additionally, Aptamer Science is an early-stage company that is evaluating aptamers for RNA delivery. While both companies have the right technical direction, at this point, they are better understood as early auxiliary stocks rather than close to commercialization.
OliPass can also be mentioned as a similar early candidate group. Although the development of RNA modulation therapeutics utilizing the OPNA platform is technically interesting, it is necessary to assess the company’s risks quite conservatively from an investment perspective. In particular, OliPass received a delisting decision from the Korean Exchange KOSDAQ Market on August 20, 2025.
Therefore, access to these early candidate companies should be cautious, taking into account both the potential of the technology and the stability of the companies.
Looking at peripheral stocks, the following classifications can be made.
First, Naybec is noted as an early delivery platform candidate. Next, Aptamer Science emerged as a candidate aptamer for RNA delivery. OliPass is included in the technology candidates but carries significant risks and is currently suspended from trading and may face a delisting decision.
Quratis is classified as a peripheral stock focusing on repRNA vaccines and CDMO, while Cellumed provides enzymes and raw materials necessary for mRNA vaccine production and is considered a management issue with trading suspensions and delisting reasons occurring.
These stocks are better understood as thematic and volatile auxiliary strata rather than core stocks centered on the main three axes such as core infrastructure.
RNA Therapeutics Conclusion
The companies related to RNA therapeutics and delivery platforms can be broadly divided into three areas.
First, Olix is responsible for the core of RNA new drug development. Second, Algenomics plays a significant role based on next-generation RNA editing technology. Third, ST Pharm forms an important foundation in terms of LNP, CDMO, and production infrastructure.
In addition, candidates like Naybec, Aptamer Science, and OliPass are classified as early-stage delivery and technology candidates, while Quratis and Cellumed can be understood as related infrastructure companies. This classification will be helpful for actual investment.
In summary, the companies attracting attention in the field of RNA new drugs are led by Olix, followed by Algenomics in technology freshness. In the areas of LNP, production, and raw material infrastructure, ST Pharm ranks first. The early delivery options include Naybec, Aptamer Science, and OliPass, while peripheral infrastructure companies consist of Quratis and Cellumed.
Consequently, considering only listed domestic companies, the core of RNA therapeutics and delivery platforms can be seen as centering on Olix, Algenomics, and ST Pharm. The remaining companies are realistically interpreted as early candidates or infrastructure-related stocks.
※ This article is intended for personal records and information sharing, not as an investment recommendation. It does not suggest the purchase or sale of specific assets or stocks.
Frequently Asked Questions (FAQ)
Q. What are the key companies in the domestic RNA therapeutics market?
The main companies in the domestic RNA therapeutics market are Olix, Algenomics, and ST Pharm.
The domestic listed RNA therapeutics market can be broadly divided into three axes. Olix leads RNA drug development and is prominent for signing license agreements with global pharmaceutical companies. Algenomics is a next-generation core stock focusing on RNA editing and correction technology, and ST Pharm is an important infrastructure provider equipped with LNP delivery technology, CDMO, and production infrastructure. These three companies form the core of the domestic RNA therapeutics and delivery platforms market.
Q. What are Olix's RNA therapeutic technologies and investment attractions?
Olix is an attractive investment with a variety of RNA interference technologies and global partnerships.
Olix is developing various RNA interference technologies such as asiRNA, cp-asiRNA, and GalNAc-asiRNA, thus possessing a multifaceted platform. In particular, GalNAc-asiRNA is a validated technology for targeted delivery to liver cells in the global market. Olix has secured massive licensing agreements with global pharmaceutical companies and is currently in an early stage of commercialization, but investors are focusing on development progress and reproducibility in technology exports. Therefore, it is considered a realistic investment target in the field of RNA therapeutics.
Q. What are the technical features and investment points of Algenomics's RNA therapeutics?
Algenomics is an innovative company developing gene therapies focused on RNA editing technology.
Algenomics possesses an RNA editing and correction platform that utilizes RNA substitution enzymes, which is different from traditional siRNA or LNP-based delivery technologies. The company employs an adenovirus-based delivery method and is conducting clinical research on hepatocellular carcinoma and glioblastoma. It has received institutional support through ODD, Fast Track, etc., validating its technology freshness, but commercialization is still in the early clinical stage, so investors need to carefully monitor technology and clinical progress.
Q. What is ST Pharm's role in the domestic RNA therapeutics market?
ST Pharm is a key infrastructure company providing RNA therapeutic production and delivery infrastructure.
ST Pharm does not develop or sell RNA therapeutics directly but focuses on CDMO for oligonucleotide therapeutics and technologies like SmartCap, STLNP, and SmartLNP related to mRNA delivery and production infrastructure. It is recognized as a representative company in Korea responsible for the LNP delivery platform and production infrastructure, and significant potential exists for infrastructure expansion alongside the growth of the RNA therapeutics market.
Q. What characteristics do early candidate companies and peripheral infrastructure companies related to domestic RNA therapeutics have?
Naybec, Aptamer Science, etc., are early-stage delivery candidates, while Quratis and Cellumed are peripheral infrastructure companies.
The domestic stock market includes Naybec, Aptamer Science, and OliPass as early delivery platform candidates under development. However, they are at a pre-commercialization stage, posing considerable investment risks and requiring careful approach. Quratis focuses on repRNA vaccines and CDMO, and Cellumed is a peripheral infrastructure company providing enzymes and raw materials for mRNA vaccine production, with some of them classified as management issues or currently facing delisting. Therefore, it is advisable to view them as thematic and volatile auxiliary strata, separate from core stocks.